To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.8026724.
Stability information for the trastuzumab biosimilar SB3 is limited to 48 h at 2–8 °C for the reconstituted solution and 24 h at up to 30 °C for diluted solutions. Extended physicochemical stability and biological activity were assessed to evaluate the advanced preparation of reconstituted and diluted SB3.
Under controlled and aseptic conditions, the stability of reconstituted and diluted SB3 was evaluated using several assessments and according to the UK’s National Health Service guidance. Reconstituted SB3 was stored at 25 ± 2 °C with 60 ± 5% relative humidity for 3 days, and subsequently diluted SB3 (0.32–4 mg/mL) was stored in an infusion bag in the absence of light at 25 ± 2 °C with 60 ± 5% relative humidity for 28 days and 5 ± 3 °C for 28 days, respectively. Physicochemical stability (appearance, pH, protein concentration, size exclusion high-performance liquid chromatography, non-reducing capillary electrophoresis–sodium dodecyl sulfate, imaged capillary isoelectric focusing), biological activity (competitive inhibition binding assay to human epidermal growth factor receptor 2 by fluorescence resonance energy transfer, anti-proliferation assay), and properties with a potential safety impact (subvisible particulates, submicronic aggregation by dynamic light scattering) were determined.
No physicochemical instability signs or biological activity changes were observed for either reconstituted or diluted SB3 up to 28 days; all stability acceptance criteria were met. No major change was noted in the proportion of molecular weight variants (high molecular weight impurity, total purity) or relative percentages of acidic, main, and basic charge isoforms of the protein. No increases in particulates or aggregates in terms of a potential safety impact were noted.
The physicochemical stability and biological activity of reconstituted and diluted SB3 are maintained for extended time periods beyond those denoted in the product labeling, which allows for advanced SB3 preparation and may reduce drug wastage and preparation time.
Samsung Bioepis Co., Ltd.
Herceptin (trastuzumab) summary of product characteristics. Roche Registration GmbH. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Accessed 28 Feb 2019.
Ontruzant (trastuzumab) summary of product characteristics. Samsung Bioepis NL B.V. https://www.ema.europa.eu/en/documents/product-information/ontruzant-epar-product-information_en.pdf. Accessed 28 Feb 2019.
Pivot X, Curtit E, Lee YJ, et al. A randomized phase I pharmacokinetic study comparing biosimilar candidate SB3 and trastuzumab in healthy male subjects. Clin Ther. 2016;38(7):1665–73. CrossRef
Pivot X, Bondarenko I, Nowecki Z, et al. Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol. 2018;36(10):968–74. CrossRef
Pivot X, Bondarenko I, Nowecki Z, et al. A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: final safety, immunogenicity and survival results. Eur J Cancer. 2018;93:19–27. CrossRef
Paul M, Vieillard V, Da Silva Lemos R, Escalup L, Astier A. Long-term physico-chemical stability of diluted trastuzumab. Int J Pharm. 2013;448(1):101–4. CrossRef
Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol. 2001;12(1):S35–41. CrossRef
Santillo M, Austin P, Goddard W, et al. A standard protocol for deriving and assessment of stability, part 2: aseptic preparations (biopharmaceuticals). 3rd ed. https://www.sps.nhs.uk/wp-content/uploads/2017/03/Stability-part-2-biopharmaceuticals-v3-April-17.pdf. Published April 2017. Accessed 1 Feb 2019.
European Pharmacopoeia: Council of Europe. 9th edn. http://online.pheur.org/EN/entry.htm.
United States Pharmacopoeia. <788> Particulate matter in injections. Revision Bulletin. https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/788_particulate_matter_in_injections.pdf. Published July 1, 2012. Accessed 1 Feb 2019.
- Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Su Jin Park
- Springer Healthcare
Advances in Therapy
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II